On this page
Erythromycin and Benzoyl Peroxide
Overview
Forms, strengths and routes
Source: NDC DirectoryRegulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 050557-001 | BENZAMYCIN | GEL | BENZOYL PEROXIDE; ERYTHROMYCIN | Prescription | AB | RLD RS |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 38 | Manufacturing (CMC) | Approved | December 5, 2014 | Standard |
| Supplement | 25 | Manufacturing (CMC) | Approved | January 27, 2003 | Standard |
| Supplement | 24 | Manufacturing (CMC) | Approved | August 28, 2002 | Standard |
| Supplement | 23 | Manufacturing (CMC) | Approved | March 21, 2002 | Standard |
| Supplement | 22 | Manufacturing (CMC) | Approved | April 17, 2001 | Standard |
| Supplement | 21 | Manufacturing (CMC) | Approved | February 6, 2001 | Standard |
| Supplement | 20 | Manufacturing (CMC) | Approved | September 27, 2000 | Standard |
| Supplement | 19 | Manufacturing (CMC) | Approved | June 11, 1997 | Standard |
| Supplement | 18 | Labeling | Approved | March 5, 1996 | Standard |
| Supplement | 17 | Labeling | Approved | June 8, 1995 | Standard |
| Supplement | 15 | Labeling | Approved | October 21, 1994 | — |
| Supplement | 13 | Manufacturing (CMC) | Approved | April 13, 1993 | Standard |
| Supplement | 14 | Manufacturing (CMC) | Approved | April 7, 1993 | Standard |
| Supplement | 12 | Manufacturing (CMC) | Approved | September 15, 1989 | Standard |
| Original application | 1 | Type 4 - New Combination | Approved | October 26, 1984 | Standard |
Review documents
- 0 · Supplement · March 6, 2003
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20190603). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Erythromycin-Benzoyl Peroxide Topical Gel is indicated for the topical treatment of acne vulgaris.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Erythromycin-Benzoyl Peroxide Topical Gel should be applied twice daily, morning and evening, or as directed by a physician, to affected areas after the skin is thoroughly washed, rinsed with warm water and gently patted dry.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Erythromycin-Benzoyl Peroxide Topical Gel is contraindicated in those individuals who have shown hypersensitivity to any of its components.
Warnings
openFDA Drug LabelingWARNINGS Pseudomembranous colitis has been reported with nearly all antibacterial agents, including erythromycin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents. Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is one primary cause of “antibiotic-associated colitis.” After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug clinically effective against C. difficile colitis.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS In controlled clinical trials, the incidence of adverse reactions associated with the use of Erythromycin-Benzoyl Peroxide Topical Gel was approximately 3%. These were dryness and urticarial reaction. The following additional local adverse reactions have been reported occasionally: irritation of the skin including peeling, itching, burning sensation, erythema, inflammation of the face, eyes and nose, and irritation of the eyes. Skin discoloration, oiliness and tenderness of the skin have also been reported. To report SUSPECTED ADVERSE REACTIONS, contact Oceanside Pharmaceuticals, at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Description
openFDA Drug LabelingDESCRIPTION Erythromycin-Benzoyl Peroxide Topical Gel contains erythromycin [(3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-[(2,6-Dideoxy-3- C -methyl-3- O -methyl-α-L- ribo -hexopyranosyl)-oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-β-D- xylo -hexopyranosyl]oxy] oxacyclotetradecane-2,10-dione]. Erythromycin is a macrolide antibiotic produced from a strain of Saccharopolyspora erythraea (formerly Streptomyces erythreus ). It is a base and readily forms salts with acids. Chemically erythromycin is C 37 H 67 NO 13 . It has the following structural formula: Erythromycin has the molecular weight of 733.94. It is a white crystalline powder and has a solubility of approximately 1 mg/mL in water and is soluble in alcohol at 25°C. Erythromycin-Benzoyl Peroxide Topical Gel also contains benzoyl peroxide for topical use. Benzoyl peroxide is an antibacterial and keratolytic agent. Chemically benzoyl peroxide is C 14 H 10 O 4 . It has the following structural formula: Benzoyl peroxide has the molecular weight of 242.23. It is a white granular powder and is sparingly soluble in water and alcohol and soluble in acetone, chloroform and ether. Each gram of Erythromycin-Benzoyl Peroxide Topical Gel contains, as dispensed, 30 mg (3%) of erythromycin and 50 mg (5%) of benzoyl peroxide in a base of purified water USP, Carbomer Homopolymer Type C, alcohol 20%, sodium hydroxide NF, docusate sodium and fragrance. Chemical Structure Chemical Structure
How Supplied / Storage and Handling
openFDA Drug LabelingHow Supplied and Compounding Directions: Size (Net Weight) NDC 68682- Benzoyl Peroxide Gel Active Erythromycin Powder (In Plastic Vial) 70% Ethyl Alcohol To Be Added 23.3 grams (as dispensed) 900-23 20 grams 0.8 grams 3 mL 46.6 grams (as dispensed) 901-46 40 grams 1.6 grams 6 mL Prior to dispensing, tap vial until all powder flows freely. Add indicated amount of room temperature 70% ethyl alcohol to vial (to the mark) and immediately shake to completely dissolve erythromycin . Add this solution to gel and stir until homogeneous in appearance (1 to 11⁄2 minutes). Erythromycin-Benzoyl Peroxide Topical Gel should then be stored under refrigeration. Do not freeze. Place a 3-month expiration date on the label. NOTE: Prior to reconstitution, store at room temperature between 15° to 30°C (59° to 86°F). After reconstitution, store under refrigeration between 2° to 8°C (36° to 46°F). Do not freeze. Keep tightly closed. Keep out of reach of children.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 68682-900-23 | 68682-900 | Oceanside Pharmaceuticals | 1 KIT in 1 CARTON (68682-900-23) * .8 g in 1 VIAL, PLASTIC (68682-924-08) * 20 g in 1 JAR (68682-923-23) | October 26, 1984 |
| 68682-901-46 | 68682-901 | Oceanside Pharmaceuticals | 1 KIT in 1 CARTON (68682-901-46) * 40 g in 1 JAR (68682-922-46) * 1.6 g in 1 VIAL, PLASTIC (68682-925-16) | October 26, 1984 |
| 68682-900 | 68682-900 | Oceanside Pharmaceuticals | — | October 26, 1984 |
| 68682-901 | 68682-901 | Oceanside Pharmaceuticals | — | October 26, 1984 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
Generated September 25, 2026 · 8 sections on this page.